Drugmaker Fine Shows SEC's Renewed Disclosure Focus

Law360 (August 30, 2019, 1:18 PM EDT) -- On Aug. 20, pharmaceutical company TherapeuticsMD Inc. settled charges by the U.S. Securities and Exchange Commission that the company had selectively disclosed market-moving information to sell-side analysts regarding potential approval of one of its drugs by the U.S. Food and Drug Administration. In the Matter of TherapeuticsMD is the first stand-alone Regulation Fair Disclosure action brought by the SEC in over five years.

The action underscores the importance of public companies maintaining policies and procedures for handling material nonpublic information in a manner compliant with Regulation FD. Life sciences companies are advised to develop standard operating procedures based upon best practices...

Stay ahead of the curve

In the legal profession, information is the key to success. You have to know what’s happening with clients, competitors, practice areas, and industries. Law360 provides the intelligence you need to remain an expert and beat the competition.


  • Access to case data within articles (numbers, filings, courts, nature of suit, and more.)
  • Access to attached documents such as briefs, petitions, complaints, decisions, motions, etc.
  • Create custom alerts for specific article and case topics and so much more!

TRY LAW360 FREE FOR SEVEN DAYS